
|Videos|March 15, 2016
SGLT2 Inhibitors and Risk for Ketoacidosis and Urinary Tract Infections
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
Advertisement
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
2
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
3
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
4
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
5

















































































































































































































